Pfizer will pay Metsera US$47.50 in cash per share, and a further US$22.50 if certain performance milestones are met, the people told the FT. The agreement represents a premium to Metsera’s Friday share price close of just over US$33 in New York.
Pfizer is closing in on a potential US$7.3 billion takeover of obesity startup Metsera, the Financial Times reported, as the drug giant looks to bolster its pipeline after the recent failure of its closely-watched weight-loss pill.
The deal could be announced as early as Monday, the FT reported, citing unidentified people familiar with the matter.
